feb event water back
one world leader analyt technolog molecular analysi
leader pharmaceut qualiti control qc market transit small
larg molecul biotechnolog macro risk like weak european market
china food gener initi growth slow miss
street revenu expect three time compani comment suggest
refresh product line-up industri contact suggest biopharma demand
strong repel competit better expect earn februari
ceo call februari like provid increas clariti
industri headwind deceler growth
premier instrument firm pharmaceut qualiti control howev
trillion pharmaceut market undergo transform
pharmaceut chemic defin oral digest drug molecular size
dalton biotechnolog therapeut activ treatment
dalton investor question water posit
market revenu growth seen downward trend
three quarter last year compound growth issu china re-
organ food safeti agenc late gener drug price
new product may revers trend grow
faster revenu revenu new product specif bioaccord
lc-m focu present compani believ
new product cycl launch start contribut
note industri particip biopharma product cite us
posit prefer vendor qc due long histori industry-
standard softwar increas level technic skill larg molecul
analysi addit see china headwind annual
food china could return compani growth
report earn februari report morn
expect guidanc growth may conserv due
earlier indic season strength question due china europ
econom soft continu robust end-market
revenu expect market condit remain strong may even
improv earlier quarter
februari host ceo confer call host focu
new technolog see emerg goal go
forward particip christoph oconnel ceo sherri buck cfo
bryan brockmeier head investor relat dial-in detail north america toll-
valuat rais fair valu fv per share fv
base pe ratio place upon earn estim per
share pe assumpt reflect pe rang
bioproduct storag servic
million except per share data
total sale
amort intang other
organ year
